Search

Your search keyword '"Combarel, David"' showing total 41 results

Search Constraints

Start Over You searched for: Author "Combarel, David" Remove constraint Author: "Combarel, David"
41 results on '"Combarel, David"'

Search Results

2. Exposure-response relationship of cabozantinib in patients with metastatic renal cell carcinoma treated in routine care

6. A Score to Predict the Clinical Usefulness of Therapeutic Drug Monitoring: Application to Oral Molecular Targeted Therapies in Cancer.

8. Brief Report: Targeted Therapies and Pancreatic Toxicity in Patients with Lung Cancer, Retrospective Study and Recommendations

12. Supplementary Figure 2 from Resistance to Selective FGFR Inhibitors in FGFR-Driven Urothelial Cancer

13. Supplementary Table 2 from Resistance to Selective FGFR Inhibitors in FGFR-Driven Urothelial Cancer

14. Supplementary Table 3 from Resistance to Selective FGFR Inhibitors in FGFR-Driven Urothelial Cancer

15. Figure 2 from Resistance to Selective FGFR Inhibitors in FGFR-Driven Urothelial Cancer

16. Figure 5 from Resistance to Selective FGFR Inhibitors in FGFR-Driven Urothelial Cancer

17. Supplementary Figure 1 from Resistance to Selective FGFR Inhibitors in FGFR-Driven Urothelial Cancer

18. Supplementary Figure 4 from Resistance to Selective FGFR Inhibitors in FGFR-Driven Urothelial Cancer

19. Table 1 from Resistance to Selective FGFR Inhibitors in FGFR-Driven Urothelial Cancer

20. Figure 4 from Resistance to Selective FGFR Inhibitors in FGFR-Driven Urothelial Cancer

21. Figure 1 from Resistance to Selective FGFR Inhibitors in FGFR-Driven Urothelial Cancer

22. Supplementary Table 1 from Resistance to Selective FGFR Inhibitors in FGFR-Driven Urothelial Cancer

23. Figure 3 from Resistance to Selective FGFR Inhibitors in FGFR-Driven Urothelial Cancer

24. Supplementary Figure 5 from Resistance to Selective FGFR Inhibitors in FGFR-Driven Urothelial Cancer

25. Data from Resistance to Selective FGFR Inhibitors in FGFR-Driven Urothelial Cancer

26. Supplementary Figure 3 from Resistance to Selective FGFR Inhibitors in FGFR-Driven Urothelial Cancer

27. Resistance to Selective FGFR Inhibitors in FGFR-Driven Urothelial Cancer

28. Abstract 3458: Resistance to selective FGFR inhibitors in FGFR-driven urothelial cancer

31. Reply to: "Therapeutic Drug Monitoring of Oral Oncology Drugs: Another Example of Maslow's Hammer" and "Therapeutic Drug Monitoring of Oral Oncology Drugs: Finding the Right Nails".

32. Abstract P4-11-24: Patient's point of view on how to promote adherence to adjuvant endocrine therapy (ET): A large french survey

35. The Effect of Concomitant Proton Pump Inhibitor and Cabozantinib on the Outcomes of Patients with Metastatic Renal Cell Carcinoma

36. Association of cabozantinib residual concentration (Ctrough) and blood clearance (Cl/F) with toxicity (tox) and progressive disease (PD) in metastatic renal cell carcinoma (mRCC) patients (pts): Results from a monocentric pharmacokinetics (PK) study.

37. Chronic Plasma Exposure to Kinase Inhibitors in Patients with Oncogene-Addicted Non-Small Cell Lung Cancer

40. Understanding and Overcoming Resistance to Selective FGFR Inhibitors across FGFR2-Driven Malignancies.

41. Phase 1 first-in-human dose-escalation study of ANV419 in patients with relapsed/refractory advanced solid tumors.

Catalog

Books, media, physical & digital resources